Csl (QX)【CSLLY】銘柄情報

Csl Ltd (QX) (CSLLY) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

16.35

( -1.68% )

買値

14.57

売値

18.30

出来高

322,903

16.29 日の範囲 16.48

16.29 52 週間の範囲 89.71

時価総額

7.883B

前日終値

16.63

始値

16.48

時刻

24.535

最終取引時間

財務取引量

US$ 5,286,777

VWAP

16.3726

平均取引量 (3 か月)

US$ 1,609,298

発行済株式数

482,130,812

配当利回り

2.92

PER

24.29

1 株当たり利益 (EPS)

2.86

歳入

15.41B

純利益

1.4B

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, ... CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.csl.com

本社

Melbourne, Australia

設立

2026

Csl Ltd (QX) is listed in the Healthcare sector of the その他OTC with ticker CSLLY. The last closing price for Csl (QX) was US$16.63. Over the last year, Csl (QX) shares have traded in a share price range of US$ 16.29 to US$ 89.71.

Csl (QX) currently has 482,130,812 shares in issue. The market capitalisation of Csl (QX) is US$7.88 billion. Csl (QX) has a price to earnings ratio (PE ratio) of 24.29.

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients...

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-1.34	-7.57490107405	17.69	17.84	16.29	953316	17.28184413	DR
4	-6.19	-27.4622892635	22.54	22.81	16.29	593799	17.87403845	DR
12	-9.53	-36.8238021638	25.88	26.61	16.29	545102	21.98051866	DR
26	-43.755	-72.7976041927	60.105	67.0632	16.29	353120	29.83509707	DR
52	-63.075	-79.4145420208	79.425	89.71	16.29	236711	39.91753584	DR
156	-86.675	-84.1300655181	103.025	109	16.29	128426	57.81616248	DR
260	-94.76	-85.2848528485	111.11	117.49	16.29	98934	66.92626062	DR